Apremilast / CAS No: 608141-41-9 CAS NO.608141-41-9

Min.Order: 0 Metric Ton
Payment Terms: L/C,T/T,

Product Details

Keywords

Apremilast / CAS No: 608141-41-9
Otezla
Apremilast (CC-10004)

Quick Details

ProName: Apremilast / CAS No: 608141-41-9
CasNo: 608141-41-9
Molecular Formula: C22H24N2O7S
Appearance: white powder?
Application: Scientific research
DeliveryTime: 7-15 working days
PackAge: net weight 25kg/drum
Port: Shanghai/ Guangzhou
ProductionCapacity: Metric Ton/Day
Purity: ≥ 99.0%
Storage: keep sealed and keep from direct light
Transportation: by air/sea/express
LimitNum: 0 Metric Ton

Superiority

ProName:Apremilast (CC-10004)（608141-41-9）
CasNo:608141-41-9
Molecular Formula:C22H24N2O7S
Appearance:Powder
Application:Scientific research
DeliveryTime:Prompt
PackAge:As required
Port:Shanghai
ProductionCapacity:1000 Gram/Week
Purity:98%
Storage:keep sealed and keep from direct light
Transportation:By Sea/Air/FedEx
LimitNum:1 Kilogram
Moisture Content:N/A
Impurity:N/A
Grade:Industrial Grade,Pharma Grade

Details

Product Name:Apremilast
Product number:BJM-041
CAS:608141-41-9
Molecular formula:

C22H24N2O7S

Molecular weight:460.5
Content:99.0%min

Apremilast / CAS No: 608141-41-9

Name: Apremilast

CAS No: 608141-41-9

Alisa: Apremilast (CC-10004) ; Otezla

MF: C22H24N2O7S

MW: 460.50

Description:

It's white powder

Density: 1.382 g/cm3
Boiling point: 741.342 °C at 760 mmHg
Flash point: 402.149 °C

Assay:99.0%min

Usage: Anti psoriatic arthritis ; PDE4 and TNF alpha inhibitors

Apremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis.Apremilast is the first oral agent that is FDA-approved for the treatment of psoriatic arthritis and offers the convenience of oral dosing compared to treatment with biopharmaceuticals. In September 2014, the USFDA approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis.It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis.